Total share-based compensation expense recognized by the Company and its subsidiaries under all equity compensation arrangements was $0.4 million and $0.7 million for the three months ended June 30, 2026 and 2025, respectively, and was $1.0 million and $1.5 million for the six months ended June 30, 2026 and 2025, respectively, which is included within Selling, general and administrative expenses in the Condensed Consolidated Statements of Operations.

All grants are time based and vest either immediately or over a period established at grant, typically with a requisite service period of one to three years for a member of the Board of Directors or an employee to vest in the share-based award, subject to discretion by Compensation Committee. There are no other substantive conditions for vesting. The Company recognizes compensation expense for equity awards, reduced by actual forfeitures as they are incurred, using the straight-line basis.

A summary of INNOVATE’s restricted stock and restricted stock unit activity is as follows:


	Number of Shares	Weighted-Average Grant Date Fair Value




Unvested - December 31, 2025	314,176	$	6.22

Vested	(98,899)	$	6.89

Unvested - June 30, 2026	215,277	$	5.91

The aggregate vesting date fair value of the restricted stock and restricted stock units which vested during the six months ended June 30, 2026 and 2025, was $1.2 million and $0.6 million, respectively. As of June 30, 2026, the total unrecognized share-based compensation expense related to unvested restricted stock and restricted stock units was $0.3 million and is expected to be recognized over the remaining weighted-average period of 0.9 years.

A summary of INNOVATE’s stock options is as follows:


	Number of Stock Options	Weighted-Average Exercise Price





Outstanding - December 31, 2025 and June 30, 2026	317,733	$	13.39









Exercisable - December 31, 2025 and June 30, 2026	217,733	$	16.94

As of June 30, 2026, the intrinsic value and weighted-average remaining life of the Company's outstanding and exercisable stock options were $1.4 million and approximately 7.9 years, respectively. The maximum contractual term of the Company's exercisable stock options is approximately ten years. As of June 30, 2026, there were 100,000 unvested stock options and $0.1 million of unrecognized share-based compensation expense related to unvested stock options which is expected to be recognized over the remaining period of 0.2 years.